Replies to post #3285 on Marker Therapeutics Inc (MRKR)

[Bio7mm]

I believe the current TPIV price reflects known risk of potential dilution. It's been public knowledge for 2 months. I believe if holders of TPIV debt are willing to take TPIV preferred which converts to common shares as repayment, that is a bullish sign for us. These creditors know more about TapImmune's prospects than we do. The TPIV pps trend is up since mid December. The current market cap is $3.8 million. A competitor, Inovio is valued at $671 million! Even if mgmt increases common TPIV shares outstanding by 500%, our market cap would still only be $20 million! A long way from $671 million! A capital raise would increase institutional confidence in TPIV and send the price even higher!